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Background: Membrane CD36 is a fatty acid transporter implicated in the pathogenesis of metabolic disease. We aimed to evalu-
ate the association between plasma CD36 levels and diabetes risk and to examine if the association was independent of adiposity 
among Danish population. 
Methods: We conducted a case-cohort study nested within the Danish Diet, Cancer and Health study among participants free of 
cardiovascular disease, diabetes and cancer and with blood samples and anthropometric measurements (height, weight, waist cir-
cumference, and body fat percentage) at baseline (1993 to 1997). CD36 levels were measured in 647 incident diabetes cases that 
occurred before December 2011 and a total of 3,515 case-cohort participants (236 cases overlap). 
Results: Higher plasma CD36 levels were associated with higher diabetes risk after adjusting for age, sex and other lifestyle fac-
tors. The hazard ratio (HR) comparing high versus low tertile of plasma CD36 levels was 1.36 (95% confidence interval [CI], 1.00 
to 1.86). However, the association lost its significance after further adjustment for different adiposity indices such as body mass 
index (HR, 1.23; 95% CI, 0.87 to 1.73), waist circumference (HR, 1.21; 95% CI, 0.88 to 1.68) or body fat percentage (HR, 1.20; 
95% CI, 0.86 to 1.66). Moreover, raised plasma CD36 levels were moderately associated with diabetes risk among lean partici-
pants, but the association was not present among overweight/obese individuals.
Conclusion: Higher plasma CD36 levels were associated with higher diabetes risk, but the association was not independent of 
adiposity. In this Danish population, the association of CD36 with diabetes risk could be either mediated or confounded by adi-
posity.
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INTRODUCTION
The prevalence of type 2 diabetes mellitus has increased dra-
matically in recent decades and now affects 422 million indi-
viduals worldwide [1]. The upsurge has been paralleled by ele-
vated rates of obesity, one of the strongest risk factors for devel-
oping type 2 diabetes mellitus [2]. The transmembrane glyco-
protein CD36 is a multi-ligand class B scavenger receptor that 
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may be involved in the development of diabetes through obe-
sogenic mechanisms. CD36 promotes the uptake of long-chain 
fatty acids in liver and skeletal muscle [3], which potentially 
leads to metabolic conditions such as dyslipidemia, obesity, 
and insulin resistance [4]. Supporting a role of CD36 in the de-
velopment of these conditions, genetic studies have shown the 
linkage between the chromosome location of the CD36 gene 
and components of the metabolic syndrome [5-7]. However, 
the association may be bi-directional, as membrane CD36 ex-
pression has also been shown to be up-regulated in adipose tis-
sues and skeletal muscle of obese individuals and patients with 
type 2 diabetes mellitus [8-10]. Therefore, adiposity could po-
tentially confound or mediate the association between CD36 
and diabetes.
Measurement of membrane CD36 requires fresh blood sam-
ples, which is typically unfeasible in large population-based 
epidemiological studies. To address this issue, Handberg et al. 
[11] recently developed a novel assay that measures circulating 
concentrations of CD36 in stored plasma samples, and a mod-
erate correlation between plasma CD36 levels and membrane 
CD36 expression in liver tissue has been reported [12], sug-
gesting that plasma CD36 levels may reflect the raised mem-
brane CD36 expression and thus be an useful biomarker for 
diabetes. Several cross-sectional studies have shown plasma 
CD36 levels to be elevated in patients with prediabetes and 
prevalent type 2 diabetes mellitus [11,13]; however, the tempo-
ral relations cannot be determined in these studies and reverse 
causality is a major concern. In the one prospective study con-
ducted to date, higher plasma CD36 levels were positively as-
sociated with risk of diabetes in age- and sex-adjusted models, 
particularly in females [14], and persisted with adjustment for 
body mass index (BMI) categories [14]. However, as no other 
covariates were included simultaneously in that model, it is not 
clear to what extent residual confounding from other impor-
tant lifestyle risk factors such as smoking, alcohol consump-
tion, physical activity, and education, as well as superior mea-
sures of adiposity (such as continuous measures of visceral fat 
and fat distribution) could explain the association between 
plasma CD36 and incident type 2 diabetes mellitus. 
Therefore, we examined the association between plasma 
CD36 levels and the risk of incident diabetes in a cohort of 
Danish men and women. Our comprehensive measures of adi-
posity and lifestyle factors allowed us to investigate whether 
the association was independent of, or modified by, adiposity.
METHODS
Study population 
The Danish Diet, Cancer and Health (DCH) study is an ongo-
ing prospective cohort study among 57,053 cancer-free partici-
pants aged 50 to 64 years of age living in the urban areas of Co-
penhagen and Aarhus [15]. At baseline from 1993 to 1997, 
participants filled in self-administered lifestyle and food fre-
quency questionnaires, and technicians collected anthropo-
metric measurements, as well as obtained a 30-mL non-fasting 
peripheral blood sample from each participant. Blood samples 
were separated into different components (e.g., plasma, serum, 
erythrocytes, buffy coat) and frozen at −150°C for long-term 
storage. The detailed study design has been described previ-
ously [15]. The study protocol was approved by the National 
Committee on Health Research Ethics and the Danish Data 
Protection Agency (KF 01-116/96) and all procedures were 
complied with the Helsinki Declaration. All participants com-
pleted informed consent at the baseline interview.
Diabetes was identified via the National Diabetes Registry 
using the personal identification number assigned to all Dan-
ish citizens. The National Diabetes Registry links administra-
tive records from the National Patient Registry, the National 
Health Service Registry, and the Danish National Prescription 
Registry, where the latter three registries kept records for hos-
pital discharge, treatment and blood glucose measurements, 
and medication purchase, respectively. Patients were included 
in the National Diabetes Registry if they (1) were diagnosed of 
diabetes before hospital discharge; (2) received podiatry care 
for diabetes; (3) had five glucose measurements within 1 year 
or two measurements per year for 5 consecutive years; or (4) 
purchased oral glucose-lowering drugs or insulin. Diabetes di-
agnoses in the National Diabetes Registry are highly valid 
(positive predictive value=89%).
We evaluated the association between plasma CD36 and di-
abetes risk in a case-cohort study nested within the DCH, 
which was initially designed for analyzing incident non-fatal 
myocardial infarction and fatal coronary heart disease (CHD) 
[16]. We included all confirmed CHD cases between baseline 
and May 2008 (n=2,063), as well as a random sub-cohort of 
individual without CHD at baseline (n=1,824) in the case-co-
hort study (Supplementary Fig. 1). In the present analysis, we 
examined diabetes as the outcome and excluded participants 
with prevalent diabetes at baseline (n=151). Incident diabetes 
cases were identified as those who were diagnosed with diabe-
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tes between baseline and December 2011 in the remaining 
participants of the case-cohort. After excluding those with 
missing covariates, the case-cohort included 648 cases (236 
within the reference sub-cohort) and 2,867 non-cases (total 
n=3,515). 
Biochemical measurements
For the current analysis, ethylenediaminetetraacetic acid 
(EDTA) plasma samples from the baseline examination were 
sent to Aarhus University Hospital for measurement of plasma 
CD36 concentrations by Handberg’s in-house enzyme-linked 
immunosorbent assay (ELISA) assay [11]. A pool of EDTA 
plasma was applied in increasing dilutions and used to pro-
duce a standard concentration curve, and phosphate-buffered 
saline served as background. Absorptions were calculated rela-
tive to the standard EDTA plasma pool and expressed as rela-
tive units. Internal controls consisting of the EDTA plasma 
pool and recombinant CD36 (generously donated by Randox, 
Laboratories, Antrim, UK) were run in duplicates and in four 
concentrations, respectively, on each plate. Analytical runs 
were accepted if one of the internal controls was within±1 
standard deviation (SD) from mean provided that the other 
control was within±2 SD. The intra-assay coefficient of varia-
tion was 11% (plasma pool, mean 0.14 arbitrary units), and to-
tal day-to-day assay coefficient of variation was 25% (plasma 
pool) and 19% (recombinant CD36). We performed batch re-
calibration by regressing plasma CD36 level on batch and age 
as well as sex, smoking status, alcohol intake, and education, 
variables associated with plasma CD36 level in our study pop-
ulation [17].
Statistical analysis 
Baseline demographic and lifestyle factors of subjected who 
developed diabetes during the follow-up and those from the 
random sub-cohort were presented as medians (5th to 95th) or 
percentages. BMI was calculated as weight (kg) divided by 
height (m) squared. Normal weight and overweight/obesity 
were defined as BMI <25 and ≥25 kg/m2. According to the 
WHO definition, abdominal obesity was defined as waist cir-
cumference >94 cm for men and >80 cm for women [18]. 
Body fat percentage was measured by bioelectrical impedance 
[19], and high body fat percentage was defined using sex-spe-
cific medians (>26.4% for men and >34.2% for women) in 
sub-cohort individuals. We estimated age- and sex-adjusted 
means for plasma CD36 in lower and higher categories of these 
adiposity indices. Plasma CD36 levels were categorized into 
tertiles based on distributions in sub-cohort participants. Cox 
proportional hazard regression using age as the underlying 
time-scale with standard inverse probability weights and ro-
bust variation was used to calculate the hazard ratio (HR) and 
95% confidence interval (CI) for diabetes according to tertiles 
of plasma CD36. The weights were incorporated to account for 
the oversampling of CHD cases. A resampling procedure was 
used to appropriately estimate the variance [20]. Model 1 in-
cluded age at baseline (continuous) and sex, and model 2 fur-
ther adjusted for smoking (never, former, current <15, 15 to 
24, ≥25 g of tobacco/day), length of school education (short 
<8, medium 8 to 10, long >10 years), alcohol intake (non-
drinker, drinker <5, 5 to 9, 10 to 19, 20 to 39, ≥40 g of alcohol/
day), and physical activity (continuous, metabolic equivalent of 
tasks/week). In subsequent models, adiposity indices (BMI, 
waist circumference, and body fat percentage) were included 
individually. In addition, we used restricted cubic spline re-
gression with 4 knots at 5%, 35%, 65%, and 95% percentiles of 
plasma CD36 concentrations to evaluate the linearity of the re-
lation between plasma CD36 and diabetes risk. Because no de-
viations from linearity were detected (P=0.77 for nonlineari-
ty), we also calculated the diabetes risk per SD of plasma 
CD36. In addition, we tested for potential interaction of plas-
ma CD36 (tertiles) with sex given the stronger associations ob-
served for women in the previous prospective study [14]. Fur-
thermore, we evaluated joint effects of plasma CD36 and adi-
posity measures, with the lowest tertile of plasma CD36 and 
the lower adiposity category used as the reference.
We used SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) 
and R version 3.1.2 (R Foundation for Statistical Computing, 
Vienna, Austria) for all analyses, and considered two-sided P 
values of <0.05 to be statistically significant.
RESULTS
Population characteristics 
The characteristics of case-cohort participants are shown in 
Table 1. The median age at baseline was 57 years for partici-
pants who developed incident diabetes and 55 years for ran-
domly selected sub-cohort individuals. In comparison to sub-
cohort participants, cases were more likely to be male, current 
smokers, and have lower education. The spearman correlations 
between plasma CD36 and BMI, waist circumference and 
body fat percentage were 0.08, 0.09, and 0.06, respectively. In 
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addition, cases had higher plasma CD36 levels, BMI, waist cir-
cumference, and body fat percentage. Within the sub-cohort, 
plasma CD36 levels were higher in participants with greater 
adiposity (P<0.05) (Fig. 1). 
Association of plasma CD36 and type 2 diabetes mellitus risk
After adjustment for age, sex and lifestyle risk factors, higher 
plasma CD36 levels were associated with higher risk of type 2 
diabetes mellitus (highest vs. lowest tertile of plasma CD36: 
HR, 1.36; 95% CI, 1.00 to 1.86) (Table 2). However, the associa-
tion was attenuated and lost its significance after further ad-
justment for BMI (highest vs. lowest tertile: HR, 1.23; 95% CI, 
0.87 to 1.73) or waist circumference (highest vs. lowest tertile: 
HR, 1.21; 95% CI, 0.88 to 1.68). Similar results were observed 
with adjustment for body fat percentage (highest vs. lowest ter-
tile: HR, 1.20; 95% CI, 0.86 to 1.66). When modelling plasma 
CD36 as a continuous variable, the HR (95% CI) for type 2 dia-
betes mellitus per SD of plasma CD36 levels was 1.10 (95% CI, 
0.96 to 1.26) in the multivariable-adjusted model, 1.05 (95% 
CI, 0.92 to 1.20) with further adjustment for BMI or waist cir-
Table 1. Baseline characteristics of participants who developed T2DM during follow-up and sub-cohort members in the Diet, 
Cancer and Health study
Variable T2DM cases Sub-cohort subjects
Number 648 1,724
Age, yr 57.0 (50.0–64.0) 55.0 (50.0–64.0)
Women, % 31.2 46.9
   Postmenopausala 68.8 58.5
   Current estrogen usea 27.2 31.9
BMI, kg/m2 28.6 (22.5–36.4) 25.6 (20.5–32.8)
Waist circumference, cm 98.0 (75.5–120.0) 89.0 (70.0–110.0)
Body fat, % 31.9 (23.4–45.5) 29.8 (19.4–42.4)
Education less than 8 years, % 44.3 33.2
Current smoker, % 50.0 37.6
Alcohol, g/day 13.5 (0.4–68.7) 13.7 (0.7–66.0)
Physical activity, METs/wk 57.9 (16.5–166.8) 60.3 (19.5–151.0)
Plasma CD36, arbitrary units 0.81 (0.10–3.42) 0.69 (0.08–3.16)
Values are presented as median (range) or percentage.
T2DM, type 2 diabetes mellitus; BMI, body mass index; MET, metabolic equivalent of task.
aAmong women. 
Fig. 1. Adjusted means of plasma CD36 according to adiposity measures: (A) high vs. low levels of body mass index (BMI); (B) 
high vs. low levels of waist circumference (WC); (C) high vs. low levels of body fat percentage. Means were adjusted for age and 
sex. Error bars indicate standard deviations. P heterogeneity values were tested between the different mean values of plasma 
CD36. 
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cumference, and 1.05 (95% CI, 0.91 to 1.20) after adjusting for 
body fat percentage. We did not find any significant interaction 
between gender and plasma CD36 in the association with dia-
betes risk (P interaction=0.10; data not shown).
Joint analysis 
The results for the joint analyses of CD36 and adiposity indices 
are shown in Fig. 2. The risk estimates associated with plasma 
CD36 levels in association with type 2 diabetes mellitus risk 
were stronger among people with lower levels of body fat per-
centage, BMI, and waist circumference. Among individuals 
with lower body fat percentage, a borderline positive associa-
tion was observed between plasma CD36 levels and higher di-
abetes risk (per SD: HR, 1.31; 95% CI, 0.97 to 1.77; P trend= 
0.08). However, among people with higher body fat percent-
age, further elevation in plasma CD36 levels was not associated 
with higher diabetes risk (per SD: HR, 1.02; 95% CI, 0.89 to 
1.18; P trend=0.75). 
DISCUSSION
In this large, prospective case-cohort study among Danish 
men and women, we found a positive association between 
plasma levels of CD36 and risk of developing diabetes after ad-
justing for lifestyle factors such as age, sex, smoking status, al-
cohol consumption, physical activity, and education status. 
However, the association was attenuated to null after addition-
al adjustment for adiposity indices such as BMI, waist circum-
Table 2. Hazard ratios and 95% confidence intervals for T2DM risk according to plasma CD36 levelsa
Variable
Tertiles of plasma CD36 Continuous
T1b T2b T3b Per SD (1.07 unit) P linearc
No. cases/No. sub-cohort 167/575 227/576 254/573
Median (range) 0.26 (0.01–0.46) 0.70 (0.46–0.99) 1.54 (0.99–8.04)
Model 1d 1 1.30 (0.95–1.77) 1.40 (1.03–1.90) 1.11 (0.96–1.27) 0.15
Model 2e 1 1.22 (0.88–1.67) 1.36 (1.00–1.86) 1.10 (0.96–1.26) 0.19
Model 2e+BMI 1 1.16 (0.83–1.62) 1.23 (0.87–1.73) 1.05 (0.92–1.20) 0.47
Model 2e+BMI+waist circumference 1 1.17 (0.84–1.63) 1.21 (0.88–1.68) 1.05 (0.92–1.20) 0.50
Model 2e+body fat percentage 1 1.17 (0.84–1.65) 1.20 (0.86–1.66) 1.05 (0.91–1.20) 0.52
T2DM, type 2 diabetes mellitus; SD, standard deviation; BMI, body mass index.
aHRs were obtained from Cox proportional hazard regression models stratified by sex, bTertiles were created based on the distribution in the 
random sub-cohort, cP values were calculated using the continuous CD36 variables, dModel 1 was adjusted for age, sex, eModel 2 was adjusted 
for age, sex, smoking status, alcohol consumption, physical activity, and education. 
Fig. 2. Hazard ratios (HRs) for joint analyses between plasma CD36 levels and adiposity indices on incident diabetes: (A) CD36 
levels and high vs. low levels of body mass index (BMI) on diabetes; (B) CD36 levels and high vs. low levels of waist circumference 
on diabetes; (C) CD36 levels and high vs. low levels of body fat percentage on diabetes. Hazard ratios are adjusted for age, sex, alco-
hol, smoking, physical activity, and education. Error bars indicate 95% confidence intervals. P trend values were calculated in sub-
groups separately. SD, standard deviation.
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ference, and body fat percentage. Therefore, the positive asso-
ciation could be either mediated or confounded by adiposity.
Previous literature suggests different functions of CD36 in 
different organs in the body. In skeletal muscle, CD36 has been 
shown to enhance insulin action to stimulate muscle glucose 
utilization [21], and in pancreatic cells, the activation of CD36 
has shown to be improved by glucolipotoxic conditions [22,23]. 
In terms of plasma CD36, to the best of our knowledge, so far 
only one prior study, a nested case-control study in Swedish 
men and women, has examined the association between plas-
ma CD36 and diabetes risk. This study found a positive associ-
ation between plasma CD36 and risk of diabetes, which per-
sisted in a model that adjusted for age, sex, overweight, and 
obesity as defined by WHO cut-points (highest vs. lowest 
quartile: HR, 2.6; 95% CI, 1.2 to 5.9; P trend ≤0.02) [14]. The 
discrepancy between the Swedish study and ours may be due 
to the differences in participant characteristics and model ad-
justments. In comparison, our study included more incident 
diabetes cases (648 in our study vs. 173 in the Swedish study). 
In addition, to minimize residual confounding we explored 
various continuous adiposity measures in a model that simul-
taneously adjusted for several diabetes risk factors. Although 
BMI is the official standard to evaluate obesity, it has several 
flaws, such as its inability to differentiate between body fat and 
muscle weight, or its inability to capture visceral fat, which may 
play a greater role in contributing to insulin resistance than 
subcutaneous fat [24,25]. Results were consistently attenuated 
after adjusting for each adiposity index, which suggested that 
the association between plasma CD36 and diabetes may be 
mediated by obesity. A recent study in China also reported a 
positive interaction between genetic CD36 variants and obesi-
ty on type 2 diabetes mellitus susceptibility; only obese people 
carrying the risk allele (rs7755) had significantly higher risk of 
developing type 2 diabetes mellitus [26]. 
Several lines of evidence support the mediating effect of obe-
sity in the relationship between CD36 and diabetes develop-
ment. Membrane CD36 transports long-chain fatty acids across 
the plasma membrane in liver, muscle and adipocytes [3]. Up-
take of fatty acids in turn increased CD36 expression through a 
peroxisome proliferator-activated receptor γ-dependent mech-
anism, which leads to enhanced efficiency of fatty acid uptake 
[27]. Thus, membrane CD36 has been shown to play an impor-
tant role from the earliest stage of ectopic fat accumulation in 
liver, skeletal muscle, and visceral tissue, which results in the 
development of overweight and obesity, and subsequently leads 
to insulin resistance and type 2 diabetes mellitus [4]. In other 
words, overweight/obesity may develop along the pathway be-
tween elevated CD36 and ultimate development of diabetes, 
and may therefore mediate the association between CD36 and 
diabetes development. In addition, membrane CD36 is a scav-
enger receptor on monocytes and macrophages that binds and 
internalizes oxidized low density lipoprotein and subsequently 
causes foam cell formation and vessel wall inflammation [28], 
which are involved in the pathophysiology of diabetes. 
While elevated plasma CD36 levels may be a causal factor 
for the development of obesity and diabetes, it is also possible 
that plasma CD36 levels are elevated by one or several compo-
nents of metabolic abnormalities (such as obesity) that ulti-
mately lead to diabetes. Metabolic syndrome includes several 
components such as obesity, dyslipidemia (triglyceride/high 
density lipoprotein), increased blood pressure and hyperglyce-
mia [29]. Among all the factors, obesity and accompanying in-
sulin resistance, as well as hyperglycemia have been shown to 
be the strongest predictors of diabetes development [30], and 
all these conditions have been shown to upregulate CD36 ex-
pression [9,10,31,32]. In addition, although the exact mecha-
nism of releasing plasma CD36 into the circulation is not clear 
yet, factors like hyperglycemia, insulin resistance, dyslipidemia 
and low-grade inflammation have been hypothesized to ele-
vate plasma CD36 levels [33], and plasma CD36 concentra-
tions have been shown to reflect the CD36 expression levels 
from tissues associated with the metabolic syndrome [28]. 
Furthermore, as reported in previous studies, plasma CD36 
levels were positively correlated with adiposity, insulin resis-
tance, and liver fat [12-14]. Moreover, genetic studies have 
shown that the location of the CD36 gene on chromosome 7q 
has been linked to components of metabolic syndrome [5-7], 
and variants in the CD36 gene have been shown to influence 
the susceptibility to the metabolic syndrome [34,35]. There-
fore, increased plasma CD36 levels may be a marker of one or 
several metabolic abnormalities that eventually lead to diabe-
tes. Thus, the association between plasma CD36 and diabetes 
may also be confounded by obesity. In the current study, we 
did not have information on other components of metabolic 
syndrome; therefore, we could not examine their impacts on 
the association between plasma CD36 and diabetes risk.
Our study has a number of important strengths. Our com-
prehensive measurements of adiposity allowed us to more fully 
assess its involvement in the association between plasma CD36 
and diabetes. In addition, the prospective design minimized the 
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potential for recall bias in exposure data (questionnaires, col-
lected bio-specimen). Moreover, compared to the previous nest-
ed case-control study [14], our current study included more di-
abetes cases with a tripled sample size. In addition, we tried to 
minimize potential confounding from adiposity by adjusting 
for three markers (BMI, waist circumference, and body fat per-
centage), thus making our study more robust than the previous 
study that adjusted for BMI alone [14]. However, some limita-
tions merit consideration. First, we identified diabetes cases via 
record linkage from the National Diabetes Registry, which 
doesn’t contain information on type of diabetes. However, since 
the rare onset of type 1 diabetes mellitus in adults [36], we as-
sume the cases included in our study represent type 2 diabetes 
mellitus. In addition, we measured plasma CD36 levels only 
once, and some measurement error was inevitable. Moreover, 
unmeasured confounding by other lifestyle factors and residual 
confounding by included covariates may exist. Furthermore, we 
did not have information on other intermediate variables for 
diabetes, such as ectopic fat measures, lipids, insulin, β-cell 
function surrogates, glucose or glycosylated hemoglobin, to 
further elucidate the underlying etiology between plasma CD36 
and diabetes. The previous nested case-control study found that 
plasma CD36 levels were not a significant independent variable 
for diabetes risk when fasting triglycerides, plasma glucose and 
insulin were simultaneously included in the multivariable mod-
els [14]. Moreover, the present study was conducted among a 
Caucasian population living in Northern Europe, and may not 
be applicable to other ethnic groups. 
In conclusion, we found a positive association between plas-
ma CD36 levels and diabetes risk among Danish men and 
women, but the association was attenuated by adjustment for 
measures of adiposity. Therefore, the positive association could 
be either mediated or confounded by adiposity. From a patho-
physiological perspective, plasma CD36 is a potential early risk 
marker for diabetes. Therefore, further longitudinal studies 
with repeated measurements of plasma CD36 and more de-
tailed measures such as ectopic fat and other blood biomarkers 
are needed to further elucidate the underlying etiology and to 
validate the findings in other ethnic groups. 
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